NACHO Consortium
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Degar, Barbara
NCT02425904: Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Active, not recruiting
2
25
Canada, US
Clofarabine, Clofarex, Clolar
Dana-Farber Cancer Institute, Sanofi, St. Baldrick's Foundation, Cookies for Kids' Cancer, North American Consortium for Histiocytosis
Langerhans Cell Histiocytosis
01/20
01/26
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting
1/2
10
US
Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16
St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach
Hemophagocytic Lymphohistiocytosis
08/25
08/26
Forlenza, Christopher J
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
Clyburn, Sara
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
Galinko, Sara
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
ASC4KIDS, NCT04925479 / 2021-001286-20: Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Recruiting
1/2
44
Europe, Japan, US, RoW
Asciminib Pediatric formulation group, ABL001, Asciminib Adult formulation group
Novartis Pharmaceuticals, Novartis Pharma AG
Myeloid Leukemia, Philadelphia Positive
06/26
11/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Degar, Barbara
NCT02425904: Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Active, not recruiting
2
25
Canada, US
Clofarabine, Clofarex, Clolar
Dana-Farber Cancer Institute, Sanofi, St. Baldrick's Foundation, Cookies for Kids' Cancer, North American Consortium for Histiocytosis
Langerhans Cell Histiocytosis
01/20
01/26
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
NCT04551131: Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Active, not recruiting
1/2
10
US
Ruxolitinib, Jakafi®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16
St. Jude Children's Research Hospital, Incyte Corporation, North American Consortium for Histiocytosis, Cures Within Reach
Hemophagocytic Lymphohistiocytosis
08/25
08/26
Forlenza, Christopher J
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
Clyburn, Sara
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
Galinko, Sara
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/25
12/29
ASC4KIDS, NCT04925479 / 2021-001286-20: Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Recruiting
1/2
44
Europe, Japan, US, RoW
Asciminib Pediatric formulation group, ABL001, Asciminib Adult formulation group
Novartis Pharmaceuticals, Novartis Pharma AG
Myeloid Leukemia, Philadelphia Positive
06/26
11/31

Download Options